Effects of Doxofylline on Pulmonary Function and Serum Levels of TGF-beta, MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease

  • Juwei Zhang
Keywords: Doxofylline, Chronic Obstructive Pulmonary Disease, Pulmonary Function, TGF-β, MMP-9, TIMP-1

Abstract

To investigate the effects of doxofylline on pulmonary function, Hemorheology and transform growth factor-β
(TGF-β), matrix metalloproteinase-9 (MMP-9) and tissue suppressor Metalloproteinase-1 (TIMP-1) levels in
patients with chronic obstructive pulmonary disease (COPD). Totally, 102 patients with COPD, treated in our
hospital from February 2015 to January 2018, were randomly divided into an observation group and a control
group according to the method of random number table, with 51 patients in either group. Patients in the control
group were given conventional treatments such as oxygen inhalation, Qiangli Pipa Syrupe, bronchodilator
(aminophylline) and antibiotics to prevent infection. The patients in the observation group were treated with
doxofylline additionally. The patients in both groups were treated continuously for 4 weeks. For the patients in
both groups, the clinical efficacies after treatment, change on pulmonary function [forced vital capacity (FVC),
maximal mid-expiratory flow curve (MMEF), peak exhalation flow (PEF) and mean pulmonary arterial pressure
(MPAP)], changes of TGF-β, MMP-9 and TIMP-1TGF-β, arterial blood gas indicator [arterial oxygen partial
pressure (PaO2) and carbon dioxide partial pressure (PaCO2)] were compared, and the occurrence of adverse
reactions during the treatment were observed. After the treatment, the total effective rate was 96.08% in the
observation group, which was significantly higher than 80.39% in the control group (P <0.05). Compared with
those before the treatment, the levels of FVC, FEV1, MMEF and PEF in both groups increased significantly,
and the levels of MPAP decreased significantly after the treatment. The changes of the above indicators were
significantly greater in the observation group than in the control group, and the differences were statistically
significant (P < 0.05). Compared with those before treatment, the serum levels of TGF-β, MMP-9 and TIMP-1
in both groups significantly decreased after the treatment, and the observation group was significantly better
than the control group (P <0.05). Compared with those before treatment, PaO2 level significantly increased,
while PaCO2 level significantly decreased in both groups after the treatment. The above indicators were better in
the observation group than in the control group, of which the differences were statistically significant (P <0.01).
The incidence of adverse reactions in the observation group was 3.92% (two cases), which was much lower than
17.65% (nine cases) in the control group (P <0.05). The clinical effect of doxofylline in the treatment of COPD
is obvious, which can significantly reduce the hemorheology indicators and serum levels of TGF-β, MMP-9 and
TIMP-1 in the patients and significantly improve the pulmonary function of the patients with high safety and
wide clinical application value.

Published
2020-02-01